S100A8 and its cognate-binding partner S100A9 exhibit potential prognostic biomarkers for reactivation of dormant tumor cells, prediction of metastatic risk and therapeutic responses failure in several malignancies, including BC (70). This evidence concerns the gene S100A8 and neoplasm.